

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C9C3DE3E454CEN.html>

Date: October 2022

Pages: 232

Price: US\$ 2,000.00 (Single User License)

ID: C9C3DE3E454CEN

Abstracts

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2022, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with

analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 28, 22, 1, 2, 19, 5 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 8, 3, 4 and 4 molecules, respectively.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).

The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of

development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's

most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved
in Therapeutics Development

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued
Products

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development
Milestones

Featured News & Press Releases

Sep 21, 2022: Ascentage Pharma announces phase I/II data of olverembatinib (HQP1351) published in the Journal of Hematology & Oncology, further validating the drug's best-in-class potential

Aug 31, 2022: Scemblix, a first-in-class CML treatment with new mechanism of action approved in Canada

Aug 29, 2022: Novartis Scemblix, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia

Aug 26, 2022: Inhibikase Therapeutics announces FDA clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Jul 22, 2022: Ascentage Pharma and Tanner Pharma Group initiate a global innovative Named Patient Program

Jul 21, 2022: Ascentage Pharma announces clinical trial application for Olverembatinib (HQP1351) approved in Canada

Jul 19, 2022: The National Medical Products Administration accepted and granted priority review designation to a new drug application for olverembatinib for the treatment of drug-resistant chronic myeloid leukemia

Jun 30, 2022: First STAMP (specifically targeting the abl myristoyl pocket) inhibitor for treatment for chronic myeloid leukaemia (CML), Scemblix (asciminib) receives NICE final draft recommendation in Great Britain

Jun 24, 2022: Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia

Jun 07, 2022: Novartis Scemblix, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Jan 05, 2022: The first commercial insurance landed in Huzhou, and Ascentage Pharma's Nerike was included in the 'Zheli Medical Insurance South Taihu Health Insurance'

Dec 14, 2021: ASH 2021 | Ascentage Pharma releases long-term clinical data of olverembatinib (HQP1351) in oral presentation demonstrating efficacy and safety

Dec 11, 2021: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Nov 25, 2021: Ascentage Pharma announces approval by NMPA for China's first approved third-generation BCR-ABL TKI HQP1351 (Olverembatinib)

Nov 22, 2021: Ascentage Pharma's olverembatinib granted orphan designation by the European Commission for the treatment of chronic myeloid leukemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, 2022

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, 2022

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C9C3DE3E454CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9C3DE3E454CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

